Scarica l'app Stockscreener
261.91
0.45%
1.17
Dopo l'orario di chiusura:
261.00
-0.91
-0.35%
Precedente Chiudi:
$260.74
Aprire:
$262.42
Volume 24 ore:
3.40M
Relative Volume:
2.28
Capitalizzazione di mercato:
$37.51B
Reddito:
$2.50B
Utile/perdita netta:
$-226.32M
Rapporto P/E:
-159.58
EPS:
-1.6412
Flusso di cassa netto:
$71.51M
1 W Prestazione:
+13.18%
1M Prestazione:
+30.36%
6M Prestazione:
+12.05%
1 anno Prestazione:
+55.74%
Intervallo 1D:
$257.07
$270.43
Intervallo di 1 settimana:
$219.50
$271.47
Portata 52W:
$131.81
$271.47
Natera Inc Stock (NTRA) Company Profile
Nome
Natera Inc
Settore
Industria
Telefono
650-249-9090
Indirizzo
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
261.91 | 37.51B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
513.03 | 190.65B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
196.19 | 138.86B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
551.50 | 43.50B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
136.01 | 38.41B | 7.23B | 1.41B | 1.09B | 4.979 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-14 | Iniziato | William Blair | Outperform |
| 2026-01-07 | Iniziato | Citigroup | Buy |
| 2025-12-02 | Ripresa | Morgan Stanley | Overweight |
| 2025-10-27 | Aggiornamento | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | Ripresa | Wells Fargo | Equal Weight |
| 2025-03-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-08 | Ripresa | Craig Hallum | Buy |
| 2024-02-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | Reiterato | BTIG Research | Buy |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-11-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | Iniziato | Bernstein | Mkt Perform |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-05 | Iniziato | UBS | Buy |
| 2023-01-18 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-04-25 | Iniziato | Stephens | Overweight |
| 2022-03-08 | Iniziato | Goldman | Buy |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-05-25 | Iniziato | Wells Fargo | Overweight |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-10-08 | Iniziato | BTIG Research | Buy |
| 2020-09-28 | Iniziato | Morgan Stanley | Overweight |
| 2020-09-17 | Iniziato | SVB Leerink | Outperform |
| 2020-06-10 | Ripresa | Piper Sandler | Overweight |
| 2020-05-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-10-05 | Iniziato | JP Morgan | Neutral |
| 2018-07-05 | Reiterato | Piper Jaffray | Overweight |
| 2017-08-07 | Reiterato | Morgan Stanley | Overweight |
| 2016-11-10 | Reiterato | The Benchmark Company | Buy |
| 2016-05-23 | Reiterato | The Benchmark Company | Buy |
| 2016-05-11 | Reiterato | The Benchmark Company | Buy |
| 2016-04-19 | Iniziato | The Benchmark Company | Buy |
| 2015-09-28 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2015-08-14 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | Iniziato | Robert W. Baird | Outperform |
| 2015-07-27 | Iniziato | Morgan Stanley | Equal-Weight |
| 2015-07-27 | Iniziato | Piper Jaffray | Overweight |
| 2015-07-27 | Iniziato | Wedbush | Neutral |
Mostra tutto
Natera Inc Borsa (NTRA) Ultime notizie
U.S. Supreme Court Rejects CareDxA’s Appeal in Natera, Inc. (NTRA) False-advertising Dispute - Insider Monkey
Price-Driven Insight from (NTRA) for Rule-Based Strategy - Stock Traders Daily
Form 4 Natera Inc For: 26 June By Investing.com - Investing.com Nigeria
Natera director Herm Rosenman sells $4.13m in common stock - Investing.com UK
Natera(NTRA.US) Officer Sells US$8.46 Million in Common Stock - Moomoo
Insider Sell Alert: Herm Rosenman Sells 16,530 Shares of Natera Inc (NTRA) - GuruFocus
Natera Inc (NTRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Natera legal officer Daniel Rabinowitz sells $8.45m in shares - Investing.com
Natera legal officer Daniel Rabinowitz sells $8.45m in shares By Investing.com - Investing.com South Africa
Natera director Herm Rosenman sells $4.13m in common stock By Investing.com - Investing.com South Africa
Natera (NTRA) director’s 10b5-1 sale leaves 4,250 shares - Stock Titan
Natera (NTRA) chief legal officer sells 33,600 shares in pre-set 10b5-1 trades - Stock Titan
Bernstein resumes Natera stock coverage with outperform rating By Investing.com - Investing.com South Africa
Natera (NTRA) Partners With Eledon To Put Prospera Into Phase 3 Kidney Trial - simplywall.st
Natera (NTRA) Receives Outperform Rating and $310 Target from Be - GuruFocus
Natera: All-Time Share Price High A Potential Caveat For Investors, Despite Promise - Seeking Alpha
Bernstein resumes Natera stock coverage with outperform rating - Investing.com UK
What's Driving Natera's Recent Stock Action, and Why Are Insiders Selling - Kavout | AI
NTRA Reiterated by Bernstein -- Price Target Announced at $310 - GuruFocus
Bernstein Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $310 - Moomoo
What's Driving Natera's Recent Stock Action - Kavout | AI
Natera, Inc. Actuals & Estimates (NASDAQ:NTRA) - TradingView
Banu Saritas-Yildirim: Signatera is Approved in Japan by FDA - Oncodaily
Eledon Teams Up With Natera on Phase 3 Study - Orange County Business Journal
NTRA Forecast — Price Target — Prediction for 2027 - TradingView
NTRA's Signatera Secures PMDA Approval for MRD Testing in CRC in Japan - The Globe and Mail
Natera’s Prospera test selected for Eledon kidney transplant trial - Investing.com UK
Goldman Sachs Maintains Natera(NTRA.US) With Hold Rating, Maintains Target Price $245 - Moomoo
Natera, Eledon Partner to Use Prospera in Phase 3 Kidney Transplant Trial - Moomoo
Natera’s Prospera test selected for Eledon kidney transplant trial By Investing.com - Investing.com Nigeria
Natera (NTRA) Stock Jumps 10.7%: Will It Continue to Soar? - Yahoo Finance
Natera And Eledon Announce Strategic Partnership For Prospera™ Monitoring In Planned Phase 3 Kidney Transplant Trial - TradingView
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial - Business Wire
Barclays Maintains Natera(NTRA.US) With Buy Rating, Cuts Target Price to $260 - Moomoo
Biotech Medical Test Leader Hits Record High, Joins 15 Others New To Best Stock Lists - Investor's Business Daily
Form 144 NATERA For: 24 June By Investing.com - Investing.com Nigeria
[144] Natera, Inc. SEC Filing - Stock Titan
This Medtech Stock Just Flashed A Buy Signal; Here's Why - Investor's Business Daily
Natera NTRA Jumps As NCCN Endorsement Fuels Bullish Targets - StocksToTrade
Why Natera (NTRA) Stock Is Up Today - Yahoo Finance
Natera Inc stock hits all-time high at 256.57 USD By Investing.com - Investing.com Australia
NTRA Maintained by BTIG -- Price Target Raised to $275 - GuruFocus
Natera Stock Jumps As NCCN Endorses Signatera MRD Test - timothysykes.com
Natera Secures Landmark Japan Nod For Signatera In Colorectal Cancer - Benzinga
Natera (NTRA) Achieves First MRD Test Approval in Japan - GuruFocus
Natera Surges As Signatera Wins Big Cancer Milestones - TipRanks
Natera (NTRA) Is Up 6.7% After First PMDA-Approved MRD Test in JapanWhat's Changed - simplywall.st
Natera Inc stock hits all-time high at 256.57 USD - Investing.com
Natera Inc Azioni (NTRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.66%
0.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):